NCT04045145已完成2 期
A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average)
研究概览
简要总结
This is a Phase 2, open-label, multiple-dose, study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 (crinecerfont) in pediatric participants (14 to 17 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be in good general health.
- •Have a medically confirmed diagnosis of classic 21-hydroxylase deficiency CAH.
- •Be on a stable regimen of steroidal treatment for CAH that is expected to remain stable throughout the study.
- •Participants of childbearing potential must be instructed on the proper use of barrier methods of contraception and agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently from screening until the final study visit or a prespecified window after the last dose of study drug, whichever is longer.
- •Participants of childbearing potential must have a negative pregnancy test at screening and negative urine pregnancy test at baseline.
- •Have a negative urine drug (for illegal drugs) and alcohol breath test at screening and baseline.
- •Be willing and able to adhere to the study regimen and study procedures described in the protocol and informed consent/assent form, including all requirements at the study center and return for the follow-up visit.
排除标准
- •Have a clinically significant unstable medical condition or chronic disease, or malignancy.
- •Had a medically significant illness within 30 days of screening.
- •Have a known or suspected differential diagnosis of any of the other known forms of classic CAH.
- •Have a history that includes bilateral adrenalectomy, hypopituitarism, or other condition requiring daily therapy with orally administered glucocorticoids.
- •Are pregnant or lactating females.
- •Have a history of epilepsy or serious head injury.
- •Have a known history of long QT syndrome or cardiac tachy-arrhythmia.
- •Have hypersensitivity to any corticotropin releasing hormone antagonists.
- •Test positive at screening for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV), or have a history of a positive result.
- •Have a recent history of alcohol or drug abuse, or current evidence of substance dependence or abuse criteria.
- •Used any anticoagulants or antiplatelet therapies within 30 days before screening.
- •Have an active bleeding disorder.
- •Used any other investigational drug within 30 days before initial screening, or plans to use an investigational drug (other than the study drug) during the study.
- •Have a blood loss ≥250 mL or donated blood within 56 days or donated plasma within 7 days before baseline.
研究组 & 干预措施
Crinecerfont 50 milligrams (mg) Twice Daily (BID)
Experimental
Crinecerfont administered orally for 14 consecutive days.
干预措施: Crinecerfont (Drug)
结局指标
主要结局
Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average)
时间窗: Baseline, Day 14
Percent changes in 17-OHP were assessed through the collection of samples from 0700 hours to 1000 hours (morning window) both prior to study drug administration (i.e., baseline) and after 14 days of study drug dosing. The 2 samples collected during this morning window at each visit were averaged and used to determine the percent change from baseline.
次要结局
- Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (24-hour Period)(Baseline, Day 14)
- Percent Change From Baseline to Day 14 in Androstenedione (Morning Window Averages)(Baseline, Day 14)
- Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) (Morning Window Averages)(Baseline, Day 14)
- Percent Change From Baseline to Day 14 in Testosterone (Morning Window Averages)(Baseline, Day 14)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal HyperplasiaCAH - Congenital Adrenal HyperplasiaNCT03525886Neurocrine Biosciences18
已完成
2 期
A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT05185622Santhera Pharmaceuticals54
已完成
2 期
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleCystic FibrosisNCT04126473Eloxx Pharmaceuticals, Inc.17
撤回
2 期
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionHepatitis B, ChronicNCT06245291Arbutus Biopharma Corporation
已完成
2 期
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseNCT03487913Palladio Biosciences31